BEIJING, Dec. 13, 2021 (Globe NEWSWIRE) — (“Genetron Health” or the “Company”, NASDAQ: GTH), a top precision oncology system company in China that specializes in featuring molecular profiling checks, early most cancers screening products and companion diagnostics growth, announced the start of the “Lung Loves New Life” genetic testing campaign, in collaboration with the China Primary Health and fitness Care Foundation. As the sole corporate donor, Genetron Health and fitness will offer absolutely free genetic tests companies (applying its 8-gene lung most cancers assay) for 10,000 Chinese lung cancer people. These checks will come to be an vital reference for people to customise their follow-up treatment regimens.

Non-little-cell lung carcinoma (NSCLC) accounts for about 80%1 of all lung cancer instances, and the frequent driver gene mutation is EGFR. In the meantime, figuring out unusual driver gene mutations is also critical to the analysis and therapy of lung cancer. This specific job will leverage 8-gene lung most cancers assays and tests services supplied by Genetron Wellbeing. It will give these “EGFR negative” lung most cancers people much more chances for optimal specific remedy.

With the enhancement of present day drugs, the therapy of lung cancer has progressively evolved from common radiotherapy and chemotherapy styles guided by pathological classification, into focused therapy products guided by molecular diagnostics. Adhering to the spirit of the “Healthy China 2030” strategy, to assist clinicians make prognosis and treatment method options for lung most cancers, and to standardize the methods, the newest version of the “Guiding Principles for the Clinical Application of New Anticancer Prescription drugs (2020 version)” states that the use of oncology drugs need to not only be based on the outcomes of pathological analysis, but should really also abide by the principles of gene detection, subsequently using specific prescription drugs to treat lung cancer.

Genetron Health’s 8-gene Lung Cancer Assay is centered on the company’s proprietary Just one-Stage Seq System, enabling…